2026-10-11T13:18:25Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34029816 2026-09-30T04:51:02Z category_388 portal_316 item_type_3 month_year_09_2026

Table 2_Two-year dynamic risk stratification and adjuvant radioiodine efficacy in initial non-distant metastatic papillary thyroid carcinoma harboring TERT promoter mutations.docx Xian-Zhao Deng (25141575) Meng-yue Liu (3642136) Chen-Tian Shen (25141578) Hong-Jun Song (20944856) Jian Wang (5901) You-Ben Fan (25141581) Quan-yong Luo (25141584) Juan Tang (437969) Xiao-er Wei (25141587) Zhong-Ling Qiu (25141590) Oncology and Carcinogenesis not elsewhere classified effect papillary thyroid cancer progression-free survival radioiodine therapy TERT-p mutation Background<p>The clinical utility of postoperative radioiodine (¹³¹I) ablation remains unclear for patients with initially diagnosed non-distant metastatic papillary thyroid carcinoma (PTC) with harboring TERT promoter(TERT-p) mutations, it is unknown whether ¹³¹I therapy reduces the risk of persistent or recurrent disease. This study investigated clinicopathological features, 2-year dynamic therapeutic responses and progression-free survival (PFS) in this specific patient cohort.</p>Methods<p>A single-center retrospective cohort study enrolled 113 eligible patients, allocated to the ¹³¹I ablation group (n=62) and non-¹³¹I group (n=51). Two-year dynamic risk stratification assessed treatment response. Kaplan–Meier curves and Cox regression models were used for survival analysis.</p>Results<p>The predominant TERT-p variant was C228T (89.4%), and most patients carried concurrent BRAF^V600E mutations. Only initial surgical approach remained an independent intergroup variable. Within 2 years, 46.0% achieved acceptable responses, associated with sex and primary surgery (p=0.036,p < 0.001). High baseline ATA risk was strongly correlated with structural residual lesions and unfavorable therapeutic response (p < 0.001).No significant between-group differences in response were observed across all ATA risk subgroups. The median follow-up was 4.6 years; 3- and 5-year PFS rates were 67.5% and 39.1%. Age ≥55 years, N1b stage and high baseline ATA risk were independent adverse predictors of PFS. Both 2-year therapeutic response and PFS at the end of follow-up exhibited no statistical differences between the ¹³¹I group and non-¹³¹I group.</p>Conclusions<p>In this retrospective observational cohort, postoperative ¹³¹I ablation was not associated with improved PFS among patients with non-distant metastatic TERT-p-mutant PTC. Advanced age, N1b lymphatic metastasis and high baseline ATA risk independently predict poor outcomes. Biologically, TERT-p mutations induce tumor dedifferentiation and impaired iodine uptake, diminishing ¹³¹I efficacy. Clinically, routine ¹³¹I yields no survival benefit for this high-risk molecular subgroup, guiding individualized surveillance and avoiding redundant ¹³¹I exposure.</p> 2026-09-30T04:51:02Z Dataset Dataset 10.3389/fonc.2026.1895987.s002 https://figshare.com/articles/dataset/Table_2_Two-year_dynamic_risk_stratification_and_adjuvant_radioiodine_efficacy_in_initial_non-distant_metastatic_papillary_thyroid_carcinoma_harboring_TERT_promoter_mutations_docx/34029816 CC BY 4.0